We use cookies for a better user experience. Read our Privacy Policy
I AgreePrevalence of insomnia has recorded a tremendous surge in the recent past, however development of an effective treatment procedure for insomnia has not yet been realized. In order to improve insomnia therapeutics, there has been an increasing emphasis on developing novel sleep-inducing medical devices along with new technologies.
Medical device manufacturers are therefore increasingly concentrating on developing smart & efficient wearable sleep-inducers with the help of advanced technologies to offer effective breathing exercises, which in turn enable patients in sleep initiation. Such devices work in conjunction with smartphone applications and are designed specifically to enable patients in falling asleep relatively faster, and staying in their sleep for sufficient amount of time.
Development of New Drug Formulations to Remain Key Strategy among Pharmaceutical Industries
Increasing efficiency of drugs, which is mainly attributed to growing bioavailability of these drugs, are likely to enhance insomnia therapeutics in the upcoming years. Development of new drug formulations for improving effectiveness of drugs is anticipated to remain a key strategy among pharmaceutical industries. Although there are several drugs available in the market for treatment of insomnia, prolonged use of majority of these drugs has been associated with dependency and addiction. This has further necessitated the requirement of treatment under medical supervision. Growing geriatric population is expected to remain a key factor driving demand for insomnia treatment. In addition, mounting incidences of mental disorders along with rising stress levels among the urban population has further created demand for insomnia therapeutics.
Insomnia prevails as the most common sleep disorder, affecting nearly 35% of the population worldwide. Cases of insomnia are categorized based on etiology into primary and comorbid subtypes. The global insomnia market is highly fragmented, along with entry barriers for new players in terms of product efficacy, innovation, and cost. However, insomnia therapeutics center on commonly available low-dose sedating antidepressants and Nonbenzodiazepines, despite introduction of several novel agents, mainly because of low awareness among patients.
The global market for insomnia will register an impressive growth during the period 2017 to 2026, according to Transparency Market Research’s (TMR) new report. Revenues from the market will reach roughly US$ 4,000 Mn by 2026-end.
North America to Remain Most Lucrative Market for Insomnia
North America accounts for the highest percentage of insomnia-affected patients. For example, according to the Centers for Disease Control and Prevention (CDC), approximately 70 Mn adults suffered from insomnia in the United States in 2016, with the male population affected being relatively higher. Increasing healthcare spending, and surging prevalence of sleep disorders will create avenues for insomnia therapeutics in the region. North America is expected to remain the most lucrative market for insomnia, with sales exhibiting the highest CAGR through 2026.
Asia-Pacific excluding Japan (APEJ) will also remain a remunerative region for growth of the insomnia market. The market expansion in APEJ can be highly attributed to increased stress level of working population along with shift-work related sleep disorders. Governments in the region are constantly focusing on improving their healthcare system along with the provision of favorable reimbursement policies, which in turn might impact the insomnia market in APEJ.
Key Research Findings from TMR’s Report
Competition Tracking
Although few players in the global insomnia market offer branded drugs, cost sensitivity prevails as a major challenge in most of the countries worldwide. Drug manufacturers are therefore focusing on the development of new cost-effective chemical entities & novel molecules for boosting their sales and obtaining larger market revenue share. Key companies profiled by TMR’s report include Pernix Therapeutics Holdings, Inc., Paratek Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, Merck & Co Company, and Mylan N.V.
Understanding of Pathophysiology of Mental Disorders Propel Advances in Insomnia Market
Insomnia, both acute and chronic, poses a high prevalence especially in elderly. The markedly underdiagnosed conditions of both present unyielding challenges for managing the condition, and is a key cornerstone on which the insomnia market draws strength. The lack of distinct pathophysiology of insomnia underpins the need for improving the approaches of assessment, including the diagnosis. Strides in evidence-based assessments and treatments for mental health problems expand the avenue in the insomnia market. The emotionally debilitating chronic insomnia in adult populations is viewed as a social burden, and impacts productivity of the workforce. There are no doubt numerous comorbid risks to the affected individuals, cardiometabolic syndrome and depression. The heterogeneity of the symptoms and the co-morbid risks underpin high unmet need for patients, thus spurring the scope of advancements in the insomnia market. Relentless efforts of medical researchers to develop an all-encompassing etiologic and pathophysiologic models of insomnia will likely enrich the landscape in the near future. These models must take into account cause, symptoms, course, comorbidities, and consequences. Further, emerging diagnostic categories add to the growth prospects. Progress being witnessed in pathophysiology of mental health problems in people suffering from insomnia has raised the standard-of-care for patient populations and will unlock new market prospects during the forecast period.
The different waves of Covid-19 has caused several severe repercussions on the health status of communities in various nations across the world. The aftermath has been associated with high economic as well as social burden on people from across the world. While policy makers are coming out with new frameworks and business owners are adopting new models of growth to sustain their bottomline, the common populace has been facing mental trauma. In various parts of the world, this has spurred the focus on mental health particularly of the elderly. Even the young population has been facing challenges due to loss of livelihoods, and are seeking family care to fight against the repercussions. All these factors are also influencing the growth dynamics of the insomnia market.
Market Taxonomy
Proceeding further, the report offers forecasts on the global market for insomnia based on a segmentation analysis. Branching the global market for insomnia into five key segments viz. technology, application, price range, product type, and region, the report delivers associated market numbers in terms of the market share comparison, Y-o-Y growth comparison, and revenue comparison. The global insomnia market has been geographically characterized by the report into Latin America, Asia-Pacific excluding Japan (APEJ), North America, Europe, Middle East & Africa (MEA), and Japan.
Region |
North America Latin America Europe Japan APEJ MEA |
Treatment Type |
Benzodiazepines Nonbenzodiazepines Antidepressants Orexin Antagonist Melatonin Antagonist Devices Other Treatment Types |
Sales Channel |
Hospital Pharmacies Retail Pharmacies and Drug Stores Online Pharmacies |
1. Global Economic Outlook
2. Global Insomnia Market - Executive Summary
3. Global Insomnia Market Overview
3.1. Introduction
3.1.1. Global Insomnia Market Taxonomy
3.1.2. Global Insomnia Market Definition
3.2. Global Insomnia Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Insomnia Market Y-o-Y Growth
3.3. Global Insomnia Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. Pricing Analysis
3.7. Product Life Cycle
3.8. PESTLE Analysis
3.9. List of Distributors
4. Global Insomnia Market Analysis and Forecast 2012-2026
4.1. Global Insomnia Market Size and Forecast By Treatment Type, 2012-2026
4.1.1. Benzodiazepines Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Nonbenzodiazepines Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Antidepressants Market Size and Forecast, 2012-2026
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Orexin Antagonist Market Size and Forecast, 2012-2026
4.1.4.1. Revenue (US$ Mn) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Melatonin Antagonist Market Size and Forecast, 2012-2026
4.1.5.1. Revenue (US$ Mn) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.1.6. Devices Market Size and Forecast, 2012-2026
4.1.6.1. Revenue (US$ Mn) Comparison, By Region
4.1.6.2. Market Share Comparison, By Region
4.1.6.3. Y-o-Y growth Comparison, By Region
4.1.7. Other Treatment Types Market Size and Forecast, 2012-2026
4.1.7.1. Revenue (US$ Mn) Comparison, By Region
4.1.7.2. Market Share Comparison, By Region
4.1.7.3. Y-o-Y growth Comparison, By Region
4.2. Global Insomnia Market Size and Forecast By Sales Channel, 2012-2026
4.2.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Retail Pharmacies and Drug Stores Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.2.3. Online Pharmacies Market Size and Forecast, 2012-2026
4.2.3.1. Revenue (US$ Mn) Comparison, By Region
4.2.3.2. Market Share Comparison, By Region
4.2.3.3. Y-o-Y growth Comparison, By Region
5. North America Insomnia Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Treatment Type
5.6. Revenue (US$ Mn) Comparison, By Sales Channel
6. Latin America Insomnia Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Treatment Type
6.6. Revenue (US$ Mn) Comparison, By Sales Channel
7. Europe Insomnia Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Treatment Type
7.6. Revenue (US$ Mn) Comparison, By Sales Channel
8. Japan Insomnia Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Revenue (US$ Mn) Comparison, By Country
8.4.1. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Treatment Type
8.6. Revenue (US$ Mn) Comparison, By Sales Channel
9. APEJ Insomnia Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Treatment Type
9.6. Revenue (US$ Mn) Comparison, By Sales Channel
10. MEA Insomnia Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Treatment Type
10.6. Revenue (US$ Mn) Comparison, By Sales Channel
11. Global Insomnia Market Company Share, Competition Landscape and Company Profiles
11.1. Company Share Analysis
11.2. Competition Landscape
11.3. Company Profiles
11.3.1. Merck & Co Company
11.3.2. Sanofi
11.3.3. Pfizer Inc.
11.3.4. Takeda Pharmaceutical Company Limited
11.3.5. Vanda Pharmaceuticals Inc.
11.3.6. Mylan N.V.
11.3.7. Teva Pharmaceutical Industries Limited
11.3.8. Sumitomo Dainippon Pharma Co., Ltd.
11.3.9. Paratek Pharmaceuticals, Inc.
11.3.10. Pernix Therapeutics Holdings, Inc.
12. Research Methodology
13. Secondary and Primary Sources
14. Assumptions and Acronyms
15. Disclaimer
List Of Table
TABLE 1 Global Insomnia Market Value (US$ Mn), 2012-2017
TABLE 2 Global Insomnia Market Value (US$ Mn), 2018-2026
TABLE 3 Global Insomnia Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Benzodiazepines Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Benzodiazepines Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Benzodiazepines Segment Market Share, By Region 2012-2017
TABLE 7 Global Benzodiazepines Segment Market Share, By Region 2018-2026
TABLE 8 Global Benzodiazepines Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Nonbenzodiazepines Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Nonbenzodiazepines Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Nonbenzodiazepines Segment Market Share, By Region 2012-2017
TABLE 12 Global Nonbenzodiazepines Segment Market Share, By Region 2018-2026
TABLE 13 Global Nonbenzodiazepines Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Antidepressants Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Antidepressants Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Antidepressants Segment Market Share, By Region 2012-2017
TABLE 17 Global Antidepressants Segment Market Share, By Region 2018-2026
TABLE 18 Global Antidepressants Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Orexin Antagonist Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Orexin Antagonist Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Orexin Antagonist Segment Market Share, By Region 2012-2017
TABLE 22 Global Orexin Antagonist Segment Market Share, By Region 2018-2026
TABLE 23 Global Orexin Antagonist Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Melatonin Antagonist Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Melatonin Antagonist Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Melatonin Antagonist Segment Market Share, By Region 2012-2017
TABLE 27 Global Melatonin Antagonist Segment Market Share, By Region 2018-2026
TABLE 28 Global Melatonin Antagonist Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Devices Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Devices Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Devices Segment Market Share, By Region 2012-2017
TABLE 32 Global Devices Segment Market Share, By Region 2018-2026
TABLE 33 Global Devices Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Other Treatment Types Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Other Treatment Types Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Other Treatment Types Segment Market Share, By Region 2012-2017
TABLE 37 Global Other Treatment Types Segment Market Share, By Region 2018-2026
TABLE 38 Global Other Treatment Types Segment Y-o-Y, By Region 2017-2026
TABLE 39 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 40 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 41 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 42 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 43 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 44 Global Retail Pharmacies and Drug Stores Segment Value (US$ Mn), By Region 2012-2017
TABLE 45 Global Retail Pharmacies and Drug Stores Segment Value (US$ Mn), By Region 2018-2026
TABLE 46 Global Retail Pharmacies and Drug Stores Segment Market Share, By Region 2012-2017
TABLE 47 Global Retail Pharmacies and Drug Stores Segment Market Share, By Region 2018-2026
TABLE 48 Global Retail Pharmacies and Drug Stores Segment Y-o-Y, By Region 2017-2026
TABLE 49 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 50 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 51 Global Online Pharmacies Segment Market Share, By Region 2012-2017
TABLE 52 Global Online Pharmacies Segment Market Share, By Region 2018-2026
TABLE 53 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 54 North America Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 55 North America Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 56 North America Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 57 North America Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 58 North America Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 59 North America Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
TABLE 60 Latin America Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 61 Latin America Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 62 Latin America Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 63 Latin America Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 64 Latin America Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 65 Latin America Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
TABLE 66 Europe Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 67 Europe Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 68 Europe Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 69 Europe Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 70 Europe Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 71 Europe Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
TABLE 72 Japan Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 73 Japan Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 74 Japan Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 75 Japan Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 76 Japan Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 77 Japan Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
TABLE 78 APEJ Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 79 APEJ Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 80 APEJ Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 81 APEJ Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 82 APEJ Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 83 APEJ Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
TABLE 84 MEA Insomnia Market Value (US$ Mn), By Country 2012-2017
TABLE 85 MEA Insomnia Market Value (US$ Mn), By Country 2018-2026
TABLE 86 MEA Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 87 MEA Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 88 MEA Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
TABLE 89 MEA Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
List Of Figures
FIG. 1 Global Insomnia Market Value (US$ Mn), 2012-2017
FIG. 2 Global Insomnia Market Value (US$ Mn) Forecast, 2018-2026
FIG. 3 Global Insomnia Market Value (US$ Mn) and Y-o-Y, 2017-2026
FIG. 4 Global Benzodiazepines Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 5 Global Benzodiazepines Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 6 Global Benzodiazepines Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 7 Global Nonbenzodiazepines Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 8 Global Nonbenzodiazepines Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 9 Global Nonbenzodiazepines Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 10 Global Antidepressants Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 11 Global Antidepressants Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 12 Global Antidepressants Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 13 Global Orexin Antagonist Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 14 Global Orexin Antagonist Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 15 Global Orexin Antagonist Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 16 Global Melatonin Antagonist Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 17 Global Melatonin Antagonist Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 18 Global Melatonin Antagonist Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 19 Global Devices Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 20 Global Devices Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 21 Global Devices Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 22 Global Other Treatment Types Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 23 Global Other Treatment Types Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 24 Global Other Treatment Types Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 25 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 26 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 27 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 28 Global Retail Pharmacies and Drug Stores Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 29 Global Retail Pharmacies and Drug Stores Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 30 Global Retail Pharmacies and Drug Stores Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 31 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 32 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 33 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 34 North America Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 35 North America Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 36 North America Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 37 North America Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 38 North America Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
FIG. 39 North America Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
FIG. 40 Latin America Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 41 Latin America Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 42 Latin America Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 43 Latin America Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 44 Latin America Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
FIG. 45 Latin America Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
FIG. 46 Europe Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 47 Europe Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 48 Europe Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 49 Europe Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 50 Europe Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
FIG. 51 Europe Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
FIG. 52 Japan Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 53 Japan Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 54 Japan Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 55 Japan Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 56 Japan Insomnia Market Value (US$ Mn), By 2012-2017
FIG. 57 Japan Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
FIG. 58 APEJ Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 59 APEJ Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 60 APEJ Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 61 APEJ Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 62 APEJ Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
FIG. 63 APEJ Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026
FIG. 64 MEA Insomnia Market Value (US$ Mn), By Country 2012-2017
FIG. 65 MEA Insomnia Market Value (US$ Mn), By Country 2018-2026
FIG. 66 MEA Insomnia Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 67 MEA Insomnia Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 68 MEA Insomnia Market Value (US$ Mn), By Sales Channel 2012-2017
FIG. 69 MEA Insomnia Market Value (US$ Mn), By Sales Channel 2018-2026